Biofrontera AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BFFTF research report →
Companywww.biofrontera.com
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria.
- CEO
- Pilar de la Huerta Martinez
- IPO
- 2018
- Employees
- 97
- HQ
- Leverkusen, DE
Price Chart
Valuation
- Market Cap
- $19.35M
- P/E
- -0.85
- P/S
- 0.22
- P/B
- 1.55
- EV/EBITDA
- -1.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 82.79%
- Op Margin
- -20.64%
- Net Margin
- -25.66%
- ROE
- -476.72%
- ROIC
- -62.07%
Growth & Income
- Revenue
- $34.07M · 18.82%
- Net Income
- $-20,131,000 · -3045.47%
- EPS
- $-13.02 · -2034.43%
- Op Income
- $-22,677,000
- FCF YoY
- -53.35%
Performance & Tape
- 52W High
- $22.68
- 52W Low
- $0.33
- 50D MA
- $22.68
- 200D MA
- $22.68
- Beta
- 0.59
- Avg Volume
- 0
Get TickerSpark's AI analysis on BFFTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BFFTF Coverage
We haven't published any research on BFFTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BFFTF Report →